HLS Therapeutics Inc.
(MENAFN- Baystreet) 09:22 AM EST - HLS Therapeutics Inc.: Announces its financial results for the three months ended September 30, 2026. All amounts are in United States dollars unless otherwise stated. Q3 2026 revenue was $14.2 million, Adjusted EBITDA was $5.0 million and cash from operations was $1.8 million, compared to $13.5 million, $4.9 million and $2.5 million, respectively. HLS Therapeutics Inc.
shares T are trading unchanged at $4.19.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment